{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"contributor": "Sabrina Tavernise contributed reporting.", "original": "By KATIE THOMAS", "person": [{"rank": 1, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}]}, "abstract": "Food and Drug Administration is probing whether faulty blood-testing machine may have compromised results of clinical trial leading to approval of Johnson & Johnson's anticlotting drug Xarelto; will seek to understand whether warning signs were apparent to drug maker. ", "type_of_material": "News", "word_count": "1420", "lead_paragraph": "A legal brief says Johnson & Johnson has been asked whether Alere\u2019s recalled INRatio blood-testing monitor compromised the anticlotting drug\u2019s trial.", "pub_date": "2016-02-23T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "F.D.A. Asks If Faulty Blood Monitor Tainted Xarelto Approval", "print_headline": "F.D.A. Seeks New Details in Approval of Xarelto   "}, "snippet": "A legal brief says Johnson & Johnson has been asked whether Alere\u2019s recalled INRatio blood-testing monitor compromised the anticlotting drug\u2019s trial.", "multimedia": [{"height": 126, "url": "images/2016/02/23/business/23DRUG/23DRUG-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/02/23/business/23DRUG/23DRUG-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 405, "url": "images/2016/02/23/business/23DRUG/23DRUG-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "405", "xlarge": "images/2016/02/23/business/23DRUG/23DRUG-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/02/23/business/23DRUG/23DRUG-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/02/23/business/23DRUG/23DRUG-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/02/23/business/fda-asks-if-faulty-blood-monitor-tainted-xarelto-approval.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Johnson & Johnson", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "Blood Clots", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Clinical Trials", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Recalls and Bans of Products", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Bayer AG", "name": "organizations"}, {"rank": "8", "is_major": "N", "value": "European Medicines Agency", "name": "organizations"}, {"rank": "9", "is_major": "N", "value": "Alere Inc", "name": "organizations"}], "blog": [], "_id": "56cb994338f0d80fb3eb22f1", "source": "The New York Times"}